Dong-A ST Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1932-01-01
- Employees
- 1.6K
- Market Cap
- -
- Website
- http://www.donga-st.com
Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02280603
- Locations
- 🇰🇷
Catholic Medical Center, Seoul, Dongdaemun-gu, Korea, Republic of
Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 223
- Registration Number
- NCT02280590
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT02267902
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, Ruddington, United Kingdom
A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT02241200
- Locations
- 🇳🇱
PRA, Zuidlaren, Netherlands
PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients
- First Posted Date
- 2014-08-12
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02214693
- Locations
- 🇰🇷
Clinical Trial Center, Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT02204722
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT02167061
- Locations
- 🇰🇷
Clinical Trial Center, Seoul National University Hospital, Seoul, Korea, Republic of
Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT02097043
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia
- First Posted Date
- 2013-08-15
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT01923545
- Locations
- 🇰🇷
Korea University GURO hospital, Seoul, Korea, Republic of
Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT01913431
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
© Copyright 2024. All Rights Reserved by MedPath